Find policies, billing codes, payers, states, and providers
Prolotherapy
Customize your policy alerts
Sign up for univerahealthcare Policy 8.01.10 alerts
Get alerted when Policy 8.01.10 changes without checking for updates manually.
Monitor payer policy activity
Defines Univera Healthcare's coverage stance on prolotherapy for musculoskeletal pain or instability and summarizes supporting evidence, guidelines, and coding. Affects providers seeking coverage for prolotherapy procedures for members.
No material clinical or coverage changes in this revision.
Coverage Determination
Overall coverage stance
Covered when ALL of the following are met
Services for prolotherapy are not considered medically necessary because they are investigational per this policy.
Prolotherapy is considered investigational as a treatment for musculoskeletal pain or instability (for example, laxity or weakness). As investigational therapy, prolotherapy services are not considered medically necessary under this policy.
Services are contract dependent. If a product does not cover prolotherapy, the medical policy criteria in this document do not apply and the service is excluded by contract.
Because prolotherapy is considered investigational for musculoskeletal pain or instability, it is not medically necessary for these indications and is therefore not covered under this policy.
Billing and Codes
Provider Requirements and Billing Guidance
Obtain prior authorization for HCPCS M0076 (E/I)
Codes may not be covered under all circumstances; prior authorization is advised when coverage is uncertain, particularly for HCPCS M0076 which the policy marks as Experimental/Investigational (E/I).
- HCPCS M0076 is listed with an (E/I) indicator in the policy; confirm authorization before scheduling.
Confirm whether member product covers prolotherapy before applying policy
If the member’s product explicitly covers prolotherapy, the medical policy criteria in this document apply; the excerpt does not list specific procedure-level prior authorization requirements. Verify product benefits to determine whether to follow the policy criteria or treat the service as excluded by contract.
- When a commercial, Medicaid, or Medicare product covers prolotherapy, follow the medical policy criteria unless a Medicare NCD or local coverage decision specifies otherwise.
- If the product does not cover prolotherapy, the policy criteria do not apply and the service may be excluded by contract.
Prefer conservative and guideline-recommended treatments first
Evidence is limited and professional guidelines are mixed; conservative or guideline-recommended therapies should be considered before prolotherapy because the literature does not consistently demonstrate effectiveness.
- Document trials of conservative care and guideline-recommended treatments prior to considering prolotherapy.
- Note that some professional guidelines state the evidence is uncertain or conditionally recommend against prolotherapy for specific indications (e.g., plantar fasciitis).
No step therapy rules specified in this policy excerpt
No step-therapy or pre-authorization sequencing requirements for prolotherapy are specified in the policy excerpt.
- Absent explicit step therapy rules in this policy, follow product-level benefit rules or prior authorization program requirements if present.
Include diagnosis, prior conservative treatments, and diagnostic/imaging confirmation
When requesting review or authorization, include the diagnosis, history of prior conservative therapies, and any imaging or diagnostic confirmation used to select patients (for example, diagnostic blocks or arthrogram/fluoroscopic confirmation when used in trials).
- Primary diagnosis and symptom duration.
- Details of conservative treatments attempted and response.
- Imaging or diagnostic confirmation (e.g., diagnostic sacroiliac joint block, arthrogram, fluoroscopic/ultrasound guidance) when relevant.
Confirm Medicare/NCD and member product coverage prior to service
Verify Medicare/NCD and product-specific coverage before ordering prolotherapy; product benefit determines whether the policy criteria apply and whether coverage is available for the service.
- Check CMS/NCD (e.g., NCD 150.7) and product benefit language.
- If Medicare product does not cover the service, follow Medicare/Medicaid product guidance (see policy product disclaimer).
Investigational designation and M0076 (E/I) may lead to denial
Because prolotherapy is designated investigational in this policy and HCPCS M0076 is marked E/I, claims or services coded M0076 risk denial as experimental/investigational (E/I).
- Services billed with M0076 may be denied as investigational per this policy.
- Obtain confirmation of coverage and prior authorization where applicable to reduce denial risk.
Coverage may be denied when product excludes prolotherapy
Coverage depends on contract and product-specific benefits; if the member’s product excludes prolotherapy the medical policy criteria do not apply and the service may be denied as not covered by the product.
- When a product excludes prolotherapy, do not rely on this medical policy for coverage.
- Confirm benefit exclusions with the payer before scheduling or billing.
Conservative Therapies and Prior Treatment
Conservative treatment requirements prior to prolotherapy
Consideration of conservative or guideline-recommended therapies is expected before prolotherapy given limited and mixed evidence
Document prior conservative treatments (e.g., physical therapy, NSAIDs, activity modification) in the clinical record when requesting coverage review.
Clinical Background
Prolotherapy is a regenerative injection technique that uses irritant solutions—commonly hypertonic dextrose and sometimes sclerosants—often combined with local anesthetic, and injected into ligaments, tendons, or joint tissues to stimulate tissue repair. The procedure is also referred to as proliferation therapy, regenerative injection therapy, or joint sclerotherapy. Although individual ingredients such as dextrose and lidocaine are approved for injection, preparations used for prolotherapy are typically compounded and are not specifically regulated or approved by the FDA as a prolotherapy product.
Definitions and Regulatory Status
Imaging and Diagnostic Requirements
Imaging not specified for prolotherapy in trials
Trials reporting positive findings often used image guidance (fluoroscopy) and arthrogram confirmation for intra-articular injections, but this policy excerpt does not specify imaging requirements for clinical practice.
- No explicit imaging requirement is stated for routine coverage or medical necessity determination.
Non-Covered Services
Prolotherapy for musculoskeletal pain or instability is not covered because this policy designates the therapy as investigational. Providers should also verify member benefit and product-specific coverage, because if a product excludes prolotherapy by contract the policy criteria do not apply.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.